Respiratory (COVID-19)

exp date isn't null, but text field is

NICE COVID-19 rapid guideline: severe asthma

Community diagnostic spirometry

The Post-COVID HUB is for:

People with post-COVID breathing difficulties and their family members and carers to get reliable information and dedicated support for physical and mental health.  

Researchers to get information on emerging evidence, research efforts and funding opportunities related to post-COVID respiratory complications. 

Healthcare professionals to get the latest guidelines on supporting people with post-COVID breathlessness.

Policy-makers and commissioners to get the latest information about the long-term respiratory impacts of COVID-19, to inform meaningful policy and service change. : useful resource for patients and professionals

Corticosteroid inhaler switches

There are temporary supply problems at present with corticosteroid inhalers please see the Table of inhaled corticosteroid equivalents for alternatives.

Cystic fibrosis (Cf)

All patients with cystic fibrosis will have a Cf care plan on sci store detailing their action plan, including admission to hospital.

All patients with cystic fibrosis should have reserve oral medication at home.

For patients on CFTR modulators - Orkambi, Symkevi and now tezacaftor - their GPs have been sent letters about the drug to drug interactions.

In the interim, and while service allows, the Cf Clinical Nurse Specialist will continue to carry out therapeutic drug monitoring for those those who have just started on treatment or who already have abnormal LFT's.

Acute Respiratory Distress Syndrome (ARDS)

Click here

(Approved by NHS Highland Clinical Expertise Group)

Editorial Information

Last reviewed: 05 February 2021

Next review: 05 August 2021

Author(s): Leslie Blaikie and Gillian Swanson, respiratory approval.

Approved By: NHS Highland Clinical Response Group

Document Id: COVID017